DETAILS
Description:
Knowledge of inosine metabolism has led to advances in immunotherapy in recent decades. Inosine monophosphate is oxidised by the enzyme inosine monophosphate dehydrogenase, yielding xanthosine monophosphate, a key precursor in purine metabolism. Mycophenolate mofetil is an anti-metabolite, anti-proliferative drug that acts as an inhibitor of inosine monophosphate dehydrogenase. It is used in the treatment of a variety of autoimmune diseases including granulomatosis with polyangiitis because the uptake of purine by actively dividing B cells can exceed 8 times that of normal body cells, and, therefore, this set of white cells (which cannot operate purine salvage pathways) is selectively targeted by the purine deficiency resulting from inherited metabolic diseases (IMD) inhibition.
| Product name | Inosine |
| CAS | 58-63-9 |
| Appearance | white powder |
| Assay | 99% |
| Storage | Cool and Protect from light |
Application
It is the important material of human body, a kind of coenzyme drug widely used in the medicine and the food industry. It can penetrate cell membrane into the cell of body directly, and make the cell in a state of feeblemindedness and anoxia continue to metabolize smoothly. And it can activate caetone acid oxides, and participate the body protein in synthesizing.
Chemical PropertiesWhite crystalline powder
OccurrenceInosine is a synthetic
UsesHas neuroprotective properties improving axonal wiring. Has been used to treat stroke patients to restore neural function.
Usescell function activator, cardiotonic
Function:
1. Used in the treatment of leucopenia and thrombocytopenia.
2.In the treatment of acute hepatitis and chronic hepatitis and liver cirrhosis, hepatic encephalopathy.
3.Used for coronary atherosclerotic heart disease (coronary heart disease), myocardial infarction,
rheumatic heart disease, cor pulmonale auxiliary drug use.
4. Used to prevent and mitigate the schistosomiasis prevention drugs caused by the heart and the liver toxicity.
5.Used for eye diseases (central retinal inflammation, optic atrophy) auxiliary drug us
Certificate of Analysis
Batch Number
Z20190412001
Production Date
2019.04.12
Batch Quantity
80 KGS
Item
Test Standard
Testing Result
Appearance
Powder
Complies
Color
White fine Powder
Complies
Particle Size
100% pass 80 mesh
Complies
Oder
Characteristic
Complies
Taste
Characteristic
Complies
Loss on Drying
≤5.0%
2.20%
Residue on Ignition
≤0.1%
0.05%
Residual acetone
≤0.1%
Complies
Residual Ethanol
≤0.5%
Complies
Heave Mentals
≤10ppm
Complies
Na
≤0.1%
<0.1%
Pb
≤3 ppm
Complies
Total Plate
<1000CFU/g
Complies
Yeast & Mold
<100 CFU /g
Complies
E. Coli
Negative
Complies
Salmonella
Negative
Complies
Conclusion: Conform with USP Standard
Storage:Closed container. dry & cool. keep away from moisture &strong light
Shelf life:24 Months
| Batch Number | Z20190412001 | ||
| Production Date | 2019.04.12 | ||
| Batch Quantity | 80 KGS | ||
| Item | Test Standard | Testing Result | |
| Appearance | Powder | Complies | |
| Color | White fine Powder | Complies | |
| Particle Size | 100% pass 80 mesh | Complies | |
| Oder | Characteristic | Complies | |
| Taste | Characteristic | Complies | |
| Loss on Drying | ≤5.0% | 2.20% | |
| Residue on Ignition | ≤0.1% | 0.05% | |
| Residual acetone | ≤0.1% | Complies | |
| Residual Ethanol | ≤0.5% | Complies | |
| Heave Mentals | ≤10ppm | Complies | |
| Na | ≤0.1% | <0.1% | |
| Pb | ≤3 ppm | Complies | |
| Total Plate | <1000CFU/g | Complies | |
| Yeast & Mold | <100 CFU /g | Complies | |
| E. Coli | Negative | Complies | |
| Salmonella | Negative | Complies | |
| Conclusion: Conform with USP Standard | |||
Shelf life:24 Months
